Press Releases
December 19, 2025
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
December 12, 2025
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
November 30, 2025
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 18, 2025
The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for “Best Bridge-Builder Institution,” “Best Biomedical Product,” “Best Medical Technology/AI Advances in Human Health,” “Best Product for Rare/Orphan Diseases,” and “Best Public Sector Innovation”
November 12, 2025
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
November 3, 2025
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
October 21, 2025
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
October 8, 2025
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
September 17, 2025
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
September 11, 2025